| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Tumor necrosis factor receptor superfamily member 25, Apo-3, Apoptosis-inducing receptor AIR, Apoptosis-mediating receptor DR3, Apoptosis-mediating receptor TRAMP, Death receptor 3, Lymphocyte-associated receptor of death, LARD, Protein WSL, Protein WSL-1, TNFRSF25, APO3, DDR3, DR3, TNFRSF12, WSL, WSL1 |
| Entrez GeneID | 8718 |
| WB Predicted band size | 45.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This TNFRSF25 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 214-242 amino acids from the Central region of human TNFRSF25. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于TNFRSF25抗体的3篇参考文献，按文献名称、作者和摘要内容简要概括：
---
1. **文献名称**: *"TNFRSF25 promotes T cell receptor-induced activation of NF-κB in regulatory T cells"*
**作者**: Kim YC, et al.
**摘要**: 研究揭示了TNFRSF25在调节性T细胞(Tregs)中通过增强TCR信号通路激活NF-κB的作用，其特异性抗体可增强Treg的免疫抑制功能，为自身免疫疾病治疗提供新靶点。
---
2. **文献名称**: *"Agonistic anti-TNFRSF25 antibody induces expansion of effector T cells and enhances antitumor immunity"*
**作者**: Zhang P, et al.
**摘要**: 报道一种激动型TNFRSF25抗体通过激活下游信号通路，促进效应T细胞扩增并抑制肿瘤生长，表明其在癌症免疫治疗中的潜在应用价值。
---
3. **文献名称**: *"TNFRSF25 modulates apoptotic signaling in chronic lymphocytic leukemia"*
**作者**: Müller L, et al.
**摘要**: 研究发现TNFRSF25抗体通过调控慢性淋巴细胞白血病(CLL)细胞的凋亡通路，增强化疗敏感性，提示其可作为CLL治疗的辅助手段。
---
(注：上述文献为示例，实际引用时需根据具体研究补充真实发表信息。)
TNFRSF25 (Tumor Necrosis Factor Receptor Superfamily Member 25), also known as death receptor 3 (DR3), is a cell surface protein belonging to the TNF receptor superfamily. It plays a critical role in regulating immune responses, particularly in T-cell-mediated immunity and inflammation. TNFRSF25 binds to its cognate ligand TL1A (TNF-like ligand 1A), initiating downstream signaling pathways such as NF-κB and MAPK, which influence cell survival, apoptosis, and cytokine production. The receptor is predominantly expressed on activated T cells, regulatory T cells (Tregs), and innate lymphoid cells, highlighting its involvement in immune homeostasis and autoimmune disorders.
Antibodies targeting TNFRSF25 have garnered interest for their therapeutic and research applications. Agonistic anti-TNFRSF25 antibodies can mimic TL1A signaling, promoting T cell activation and expansion, which may enhance antitumor immunity or vaccine efficacy. Conversely, antagonistic antibodies block TL1A-TNFRSF25 interaction, potentially suppressing pathological inflammatory responses in autoimmune diseases like rheumatoid arthritis, inflammatory bowel disease, or multiple sclerosis. Preclinical studies in animal models suggest that modulating TNFRSF25 signaling could fine-tune immune activation or tolerance, depending on the context. However, the duality of its pro-inflammatory and regulatory roles necessitates careful evaluation in clinical settings. Current research focuses on optimizing antibody specificity, understanding receptor-ligand dynamics, and exploring combination therapies to harness TNFRSF25's immunomodulatory potential safely.
×
